Hemolysis in a Patient with a Prosthetic Valve
A 48-year-old man with a mechanical mitral valve presents with fatigue and dark urine. Labs: hemoglobin 8.2 g/dL (baseline 12.5), MCV 98 fL, reticulocyte count 6.5%, LDH 1,240 U/L (reference 140–280), haptoglobin <10 mg/dL, total bilirubin 3.1 mg/dL with indirect 2.6 mg/dL, creatinine 1.0 mg/dL. Peripheral smear shows schistocytes (2–3 per high-power field), polychromasia, and no spherocytes. Direct antiglobulin test (DAT) is negative. The patient's international normalized ratio (INR) is 2.4 on warfarin.
1. Classify the anemia and explain how the laboratory data localize the hemolysis.
Read the worked answer
Classification: Normocytic (MCV 98) anemia with reticulocytosis (6.5%) and biochemical evidence of hemolysis - this is a hemolytic anemia, and the schistocytes indicate a microangiopathic process.
Localization of hemolysis:
- Intravascular hemolysis markers: markedly elevated LDH, undetectable haptoglobin, hemoglobinuria (dark urine). These indicate red cell destruction within the vasculature.
- Extravascular markers: indirect hyperbilirubinemia is present but modest; splenic sequestration would typically show less LDH elevation and preserved haptoglobin.
- DAT negative argues against autoimmune hemolysis.
- Schistocytes indicate mechanical fragmentation, consistent with a mechanical prosthetic valve (valve-related hemolysis).
Why not other causes:
- TTP/HUS would usually show thrombocytopenia and renal injury; platelets are not given but creatinine is normal.
- DIC would show prolonged PT/aPTT, low fibrinogen, and thrombocytopenia; INR 2.4 is explained by warfarin.
- The absence of spherocytes argues against hereditary spherocytosis.
Conclusion: Mechanical (valve-related) microangiopathic hemolytic anemia.
2. What additional laboratory tests would you order, and how would you use them to guide management?
Read the worked answer
Additional tests:
- CBC with platelet count - to exclude TTP/HUS and assess severity.
- Peripheral smear review by a pathologist - quantify schistocytes (>1% supports microangiopathic process).
- Coagulation panel (PT/INR, aPTT, fibrinogen, D-dimer) - to exclude DIC and confirm warfarin effect.
- Iron studies, B12, folate - to assess for coexisting nutritional deficiency that could blunt the reticulocyte response.
- Renal function and urinalysis - to assess for hemoglobinuria and renal involvement.
- Echocardiography - to evaluate valve function (paravalvular leak, dehiscence, thrombosis) as the mechanical cause.
- LDH, haptoglobin, bilirubin, reticulocyte count - to trend hemolysis over time.
Use in management:
- If schistocytes are confirmed and valve dysfunction is present, surgical or percutaneous intervention may be needed.
- If hemolysis is mild and stable, supportive care with iron supplementation and monitoring may suffice.
- Ensure anticoagulation is therapeutic (INR 2.4 is in range for a mechanical mitral valve, typically 2.5–3.5; consider whether target should be higher).
- Transfuse if symptomatic or hemoglobin falls further.
Key teaching point: In a patient with a mechanical valve, a microangiopathic hemolytic picture with negative DAT should prompt evaluation for valve dysfunction rather than an autoimmune workup.